Three medical societies claim recent studies have overestimated the potential harms from lung cancer screening and may be deterring patients. Not everyone agrees.

Incyte is looking to expand the use of its PD-1 blocker Zynyz to treat non-small cell lung cancer. The FDA’s rejection did ...

Nanjing Leads Biolabs Co., Ltd. ('Leads Biolabs' or the 'Company,' Stock Code: 9887.HK) announced on March 6, 2026 that the ...

Breakthrough immunotherapy trials are showing unprecedented responses in a subset of rectal cancer patients, hinting at a ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven ...

Learn how to tell the difference between these two common symptoms.

Radon, an odorless radioactive gas that seeps from soil into homes, is responsible for an estimated 21,000 lung cancer deaths each year in the United States. That figure, drawn from federal risk ...

Scientists at the University of Geneva have created a new AI system that can predict the chances of cancer spreading to other parts of the body. The new AI system, named MangroveGS, studies ...

Following multiple meetings with the FDA, ImmunityBio submitted additional information requested by the Agency to support its supplemental BLA (sBLA) for papillary ...

The neuroendocrine carcinoma market is experiencing steady growth driven by rising disease prevalence and improved diagnostic capabilities. Advancements in targeted therapies and immunotherapies ...

Kaposi sarcoma-associated herpesvirus testing is not routinely performed on donors or reci ...

Women and girls bear the brunt of collapsing healthcare and mass displacement Medical staff describe an exponential rise in maternal and neo-natal health ...